Journal: Nature Communications

Article Title: Streamlined metal-based hydrogel facilitates stem cell differentiation, extracellular matrix homeostasis and cartilage repair in male rats

doi: 10.1038/s41467-025-59725-y

Figure Lengend Snippet: a Experimental design time flowchart and the illustration of the recruitment process of BMSCs during cartilage repair. b Immunofluorescent staining of CD44 and CD90 at 7 or 14 days. c Experimental design time flowchart. d WB analysis of protein levels of COL2A1, Aggrecan, MMP13, ADAMTS5, Ihh, and PTHrP in rats. Blots are representative of three independent experiments. e Quantitative analysis of WB. Data were presented as the mean ± SD ( n = 3 independent experiments). * P < 0.05, ** P < 0.01, and *** P < 0.001. Statistical comparisons were performed using the unpaired two-sided Student’s t -test. f Macroscopic observation of cartilage defect at 4- and 8-weeks post-surgery. g Heatmap of variables of macroscopic scoring at 4 and 8 weeks. h ICRS macroscopic scores of different groups. Data were presented as the mean ± SD ( n = 4 independent experiments). * P < 0.05, ** P < 0.01, and *** P < 0.001. Statistical comparisons were performed using one-way ANOVA with Tukey’s test. i Representative three-dimensional (3D) images of the rat knee joint, 2D images in the coronal and sagittal planes were reconstructed by micro-CT. (3D images of subchondral bone were obtained by reconstructing the green areas in 2D images using processing software). j Quantitative analysis of osteophyte volume. k – o BMD, BV/TV, Tb. N, Tb. Th, and Tb. Sp were quantified by micro-CT. Data were presented as the mean ± SD ( n = 4 independent experiments). * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001. Statistical comparisons were performed using one-way ANOVA with Tukey’s test in j – o Source data are provided as a Source Data file.

Article Snippet: CD44 Polyclonal, CD90 Monoclonal, MMP13 polyclonal, aggrecan polyclonal, and PTHLH polyclonal antibodies were purchased from Proteintech Group, Inc. Cyclopamine was purchased from MedChemExpress (Shanghai, China).

Techniques: Staining, Micro-CT, Software

Journal: Cancer immunology research

Article Title: Combined CD44- and CD25-targeted Near-Infrared Photoimmunotherapy Selectively Kills Cancer and Regulatory T cells in Syngeneic Mouse Cancer Models

doi: 10.1158/2326-6066.CIR-19-0517

Figure Lengend Snippet: A. Representative dot plots of live, FOXP3+CD25+CD4+ T cells via flow cytometry in MC38-luc tumors (1 day after NIR light irradiation) treated with CD25-targeted NIR-PIT, combined CD44- and CD25-targeted NIR-PIT, and control tumors. B. Cell count ratios of CD25+FOXP3+ cells in CD3+ CD4+ cells within the tumors (n=5/group from single experiment, mean+/− SEM, *p<0.05, Tukey-Kramer test; NS: not significant. C. Representative multi-color immunofluorescence images (×200) for CD8+ T cells, CD4+ T cells, and Tregs infiltrating in TME of MC38-luc tumors (7 days after NIR light irradiation, n=3/group) treated with CD25-targeted NIR-PIT, CD44-targeted NIR-PIT, combined CD44- and CD25- targeted NIR-PIT (right side), and control tumors (left side). CD8+ cells, CD4+FOXP3– cells, and CD4+FOXP3+ cells were regarded as CD8+ T cells, CD4+ T cells, and Tregs, respectively. Scale bar represents 100um. D. Cell counts per megapixel in multi-color immunofluorescence images to quantitatively evaluate CD4+ T cells, CD8+ T cells, and Tregs infiltrating into the TME. (n=3/group from single experiment, mean+/− SEM, *p<0.05, t-test.

Article Snippet: An anti-mouse/human CD44 (IM7) and anti-mouse CD25 (PC-61.5.3) were purchased from Bio X Cell.

Techniques: Flow Cytometry, Irradiation, Cell Counting, Immunofluorescence

Journal: Cancer immunology research

Article Title: Combined CD44- and CD25-targeted Near-Infrared Photoimmunotherapy Selectively Kills Cancer and Regulatory T cells in Syngeneic Mouse Cancer Models

doi: 10.1158/2326-6066.CIR-19-0517

Figure Lengend Snippet: A-C.Immunohistochemistry staining was performed to examine CD44 expression as a target for NIR-PIT within (A) MC38-luc, (B) LL/2, and (C) MOC1 tumors without treatment. Representative images from at least three samples are shown (×200).

Article Snippet: An anti-mouse/human CD44 (IM7) and anti-mouse CD25 (PC-61.5.3) were purchased from Bio X Cell.

Techniques: Immunohistochemistry, Staining, Expressing

Journal: Cancer immunology research

Article Title: Combined CD44- and CD25-targeted Near-Infrared Photoimmunotherapy Selectively Kills Cancer and Regulatory T cells in Syngeneic Mouse Cancer Models

doi: 10.1158/2326-6066.CIR-19-0517

Figure Lengend Snippet: A. NIR-PIT regimen. Bioluminescence and fluorescence images were obtained at each time point as indicated. B. Real-time in vivo IR700 fluorescence imaging of tumor-bearing mice before and approximately 10 minutes after NIR-PIT. The yellow arrows indicate the tumor locations. C. In vivo bioluminescence imaging of tumor-bearing mice before and after NIR-PIT at the indicated timepoints. D. Quantitative analysis of luciferase activity before and after NIR-PIT in tumor-bearing mice. n≥10/group, mean+/− SEM, *p<0.05, control vs. the other groups, Tukey-Kramer test; **p<0.05, CD44-taregeted NIR-PIT vs. combined NIR-PIT group, Tukey-Kramer test. E. Tumor growth in control and all NIR-PIT–treated groups. n≥10/group, mean+/− SEM, *p<0.05, control vs. the other groups, Tukey-Kramer test; **p<0.05, CD44-targeted NIR-PIT vs. combined NIR-PIT group, Tukey-Kramer test. F. Survival curves for control and NIR-PIT–treated groups. n≥10/group, *p<0.05, **p<0.01, Log-rank test; NS: not significant.

Article Snippet: An anti-mouse/human CD44 (IM7) and anti-mouse CD25 (PC-61.5.3) were purchased from Bio X Cell.

Techniques: Fluorescence, In Vivo, Imaging, Luciferase, Activity Assay

Journal: Cancer immunology research

Article Title: Combined CD44- and CD25-targeted Near-Infrared Photoimmunotherapy Selectively Kills Cancer and Regulatory T cells in Syngeneic Mouse Cancer Models

doi: 10.1158/2326-6066.CIR-19-0517

Figure Lengend Snippet: A. NIR-PIT regimen. IR700 fluorescence images were obtained at each time point as indicated. B. Real-time in vivo IR700 fluorescence imaging of tumor-bearing mice before and approximately 10 minutes after NIR-PIT. The yellow arrows indicate the tumor locations. C. Tumor growth in control and all NIR-PIT–treated groups. n=9–10/group, mean+/− SEM, *p<0.05, control vs. the other groups, Tukey-Kramer test; **p<0.05, CD44-targeted NIR-PIT vs. combined NIR-PIT group, Tukey-Kramer test. D. Survival curves for control and NIR-PIT–treated groups. n=9–10/group, *p<0.05, **p<0.01, Log-rank test; NS: not significant.

Article Snippet: An anti-mouse/human CD44 (IM7) and anti-mouse CD25 (PC-61.5.3) were purchased from Bio X Cell.

Techniques: Fluorescence, In Vivo, Imaging

Journal: Cancer immunology research

Article Title: Combined CD44- and CD25-targeted Near-Infrared Photoimmunotherapy Selectively Kills Cancer and Regulatory T cells in Syngeneic Mouse Cancer Models

doi: 10.1158/2326-6066.CIR-19-0517

Figure Lengend Snippet: A. NIR-PIT regimen. IR700 fluorescence images were obtained at each time point as indicated. B. Real-time in vivo IR700 fluorescence imaging of tumor-bearing mice before and approximately 10 minutes after NIR-PIT. The yellow arrows indicate the tumor locations. C. Tumor growth in control and all NIR-PIT–treated groups. n=9–10/group, mean+/− SEM, *p < 0.05, control vs. the other groups, Tukey-Kramer test; **p<0.05, CD44-targeted NIR-PIT vs. combined NIR-PIT group, Tukey-Kramer test. D. Survival curves for control and NIR-PIT–treated groups. n=9–10/group, **p<0.01, Log-rank test; NS: not significant.

Article Snippet: An anti-mouse/human CD44 (IM7) and anti-mouse CD25 (PC-61.5.3) were purchased from Bio X Cell.

Techniques: Fluorescence, In Vivo, Imaging

Journal: Cancer immunology research

Article Title: Combined CD44- and CD25-targeted Near-Infrared Photoimmunotherapy Selectively Kills Cancer and Regulatory T cells in Syngeneic Mouse Cancer Models

doi: 10.1158/2326-6066.CIR-19-0517

Figure Lengend Snippet: FOXP3+CD25+CD4+ Tregs limit antitumor immunity through suppression of effector T cells and NK cells by inhibitory cytokines and cytolysis, as well as by metabolic disruption with IL2 consumption and modulation of DC maturation or function. Combined CD44- and CD25-targeted NIR-PIT induces immunogenic cell death in CD44+ tumors and selectively depletes Tregs with high CD25 expression. Step1: The process of immunogenic cell death caused by CD44-targeted NIR-PIT induces DC maturation. Step 2: Treg depletion induces activation and expansion of effector T cells and simultaneously, differentiation into tumor-specific T cells. Taken together, this combined NIR-PIT results in effective tumor killing and promotion of long-lasting antitumor immunity.

Article Snippet: An anti-mouse/human CD44 (IM7) and anti-mouse CD25 (PC-61.5.3) were purchased from Bio X Cell.

Techniques: Expressing, Activation Assay